JPH11508130A - 前赤血球段階のマラリアのポリペプチド分子 - Google Patents
前赤血球段階のマラリアのポリペプチド分子Info
- Publication number
- JPH11508130A JPH11508130A JP9502711A JP50271197A JPH11508130A JP H11508130 A JPH11508130 A JP H11508130A JP 9502711 A JP9502711 A JP 9502711A JP 50271197 A JP50271197 A JP 50271197A JP H11508130 A JPH11508130 A JP H11508130A
- Authority
- JP
- Japan
- Prior art keywords
- lsa
- polypeptide
- molecule
- sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 130
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 89
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 50
- 201000004792 malaria Diseases 0.000 title claims description 11
- 230000000925 erythroid effect Effects 0.000 title description 9
- 239000000427 antigen Substances 0.000 claims abstract description 64
- 102000036639 antigens Human genes 0.000 claims abstract description 64
- 108091007433 antigens Proteins 0.000 claims abstract description 64
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 210000003046 sporozoite Anatomy 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 241000223960 Plasmodium falciparum Species 0.000 claims description 22
- 230000003053 immunization Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 150000007523 nucleic acids Chemical group 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 12
- 229960005486 vaccine Drugs 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000004816 latex Substances 0.000 claims description 7
- 229920000126 latex Polymers 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 230000000078 anti-malarial effect Effects 0.000 claims description 4
- 239000003430 antimalarial agent Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims 4
- 230000008105 immune reaction Effects 0.000 claims 3
- 102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 claims 2
- 101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 claims 2
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 244000045947 parasite Species 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 18
- 108010028921 Lipopeptides Proteins 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 241000282579 Pan Species 0.000 description 15
- 241000282577 Pan troglodytes Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000003252 repetitive effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004976 peripheral blood cell Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 210000001563 schizont Anatomy 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 241000223830 Plasmodium yoelii Species 0.000 description 5
- 101710084593 Sensory histidine kinase/phosphatase NtrB Proteins 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 125000003473 lipid group Chemical group 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001589 lymphoproliferative effect Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000009182 Parasitemia Diseases 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 239000013616 RNA primer Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108010029451 boc-Phe-((R)-CH(OH)CH2NH)-Phe-Glu-Phe-NH2 Proteins 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000282709 Aotus trivirgatus Species 0.000 description 1
- XVBDDUPJVQXDSI-PEFMBERDSA-N Asn-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVBDDUPJVQXDSI-PEFMBERDSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical group OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- BFEZQZKEPRKKHV-SRVKXCTJSA-N Glu-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O BFEZQZKEPRKKHV-SRVKXCTJSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- NBJAAWYRLGCJOF-UGYAYLCHSA-N Ile-Asp-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NBJAAWYRLGCJOF-UGYAYLCHSA-N 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101150055501 K1 gene Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003606 oligomerizing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- -1 poly (DL-alanine)-(L-lysine) Chemical compound 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/822—Protozoa
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.図2に示されているアミノ酸配列のアミノ酸を連続して10以上含有するポ リペプチド分子であって、以下のポリペプチド: を除くポリペプチド分子。 2.請求項1に記載の分子であって、前記配列のアミノ酸を20以上連続して含 有していることを特徴とする分子。 3.請求項2に記載の分子であって、前記配列のアミノ酸を50以上連続して含 有していることを特徴とする分子。 4.請求項1〜3の何れか1項に記載の分子のうちの1つと70%以上の相同性 を示すポリペプチド分子。 5.以下の配列: と70%以上の相同性を示すことを特徴とするポリペプチド分子。 6.請求項1〜4の何れか1項に記載のポリペプチド分子であって、図3に図 示されている配列と少なくとも70%の相同性を示すことを特徴とするポリペプチ ド分子 7.請求項1〜6の何れか1項に記載のポリペプチドを1以上および薬学的賦 形剤を1以上含有することを特徴とする免疫原性組成物。 8.他の免疫原成分に加えて、請求項1〜6の何れか1項に記載のポリペプチ ド分子を含有する抗マラリアワクチン組成物。 9.請求項8に記載のワクチン組成物であって、さらに1以上のエピトープを 含み、且つLSA-1、SALSAまたはSTARP分子からなる群から得られる 分子を含有することを特徴とする組成物。 10.請求項9に記載の組成物であって、2以上の免疫原を含み、第1の免疫原 が、以下のポリペプチド: −図2のポリペプチド、 −NRI、 −NRII から選択され、第2の免疫原が、SALSA、SALSAI、およびSA LSAIIからなる群から選択されることを特徴とする組成物。 11.請求項1〜6の何れか1項に記載のポリペプチド分子を特異的に認識する ポリクローナル抗体またはモノクローナル抗体。 12.熱帯熱マラリア原虫に感染している可能性を有する個体中のマラリアをイ ンビトロで診断する方法であって、組織または生体液に存在する可能性のある抗 体と前記ポリペプチド分子との免疫反応を可能する条件下で、個体から得た組織 または生体液を請求項1〜8の何れか1項に記載の分子と接触せしめることと、 形成される可能性のある抗原/抗体複合体をインビトロで検出することを含んで なる方法。 13.請求項12に記載の方法であって、請求項1〜6の何れか1項に対応する ポリペプチド分子、およびスポロゾイト段階の抗原、すなわち、LSA-1、SA LSAまたはSTARP から得られる他の分子との混合物と組織または生体液 を接触せしめることを特徴とする方法。 14.熱帯熱マラリア原虫に感染している可能性を有する個体中のマラリアをイ ンビトロで診断する方法であって、生体組織に存在する可能性のある熱帯熱マラ リア原虫に特異的なタンパク質と前記抗体との間のインビトロ免疫反応を可能に する条件下で、個体から得た組織または生体液を請求項11に記載の抗体と接触 せしめることと、形成される可能性のある抗原/抗体複合体をインビトロで検出 することを具備することを特徴とする方法。 15.請求項12または13の何れかに記載のインビトロマラリア診断用キット であ って、 請求項1〜6の何れか1項に記載の分子を少なくとも1つまたは数個と 、 反応に適した媒質を構成する試薬であって、免疫反応によって産生され た抗原/抗体複合体の検出を可能にする試薬と を具備することを特徴とし、特に上述のポリペプチド分子がラベルされて いない場合、これらの試薬はラベルを有することができ、またはラベルされた試 薬によって認識することができるような試薬であるキット。 16.インビトロマラリア診断用キットであって: −請求項11に記載の抗体と、 反応に適した媒質を構成する試薬であって、免疫反応によって産生され た抗原/抗体複合体の検出を可能にする試薬と を具備することを特徴とし、特に上述のポリペプチド分子がラベルされて いない場合、これらの試薬はラベルを有することができ、または順次、ラベルさ れた試薬によって認識することができるような試薬であるキット。 17.抗マラリアワクチンの調製における請求項1〜6の何れか1項に記載のポ リペプチド分子の使用。 18.マラリア治療を目的とした医薬品を調製するための、請求項11に記載の 1以上のポリクローナル抗体またはモノクローナル抗体の使用。 19.薬学的に受容できる賦形剤とともに、活性物質として請求項11に記載の ポリクローナル抗体またはモノクローナル抗体を1以上含有する薬学的組成物。 20.以下の配列: (a)図1の配列認識番号1に図示されているヌクレオチド鎖のつながり 、または (b)図2の配列認識番号2に図示されているヌクレオチド鎖のつながり 、 (c)図1もしくは図2のものと70%以上の相同性を示す鎖のつながり、 または (d)(a)、(b)もしくは(c)に示されているものと相補的なヌクレオチド鎖 のつながり のうちの1つによって特徴付けられる核酸配列。 21.請求項1〜6の何れか1項に記載のポリペプチド分子をコードする配列を 含有する請求項20に記載の核酸。 22.請求項20または請求項21に記載のヌクレオチド配列をクローニングす るための、および/または上述の配列によってコードされるポリペプチドを発現 させるための組換えベクターであって、複製に不可欠でない部位のうちの1つに 前記配列を含み、特に前記ベクターが、プラスミド型、コスミド型またはファー ジ型であるようなベクター。 23.請求項22に記載のベクターであって、該ベクターが、No.I-1573でCN CMに寄託され、pK1.2.と称されるプラスミドであることによって特徴付けら れるベクター。 24.請求項1〜6の何れか1項に記載のポリペプチド分子および該分子を吸着 させる支持体からなる化合物。 25.請求項24に記載の化合物であって、該支持体がラテックスもしくはポリ スチレンの小球またはビーズからなることを特徴とする化合物。 26.マラリアに感染している、または感染している可能性のある個体を免疫化 するための請求項24および25の何れか1項に記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9507007A FR2735478B1 (fr) | 1995-06-13 | 1995-06-13 | Molecules polypeptidiques de stade pre-erythrocytaire du paludisme |
FR95/07007 | 1995-06-13 | ||
PCT/FR1996/000894 WO1996041877A2 (fr) | 1995-06-13 | 1996-06-12 | Molecules polypeptidiques de stade pre-erythrocytaire du paludisme |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008139896A Division JP2009000104A (ja) | 1995-06-13 | 2008-05-28 | 前赤血球段階のマラリアのポリペプチド分子 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11508130A true JPH11508130A (ja) | 1999-07-21 |
Family
ID=9479927
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9502711A Pending JPH11508130A (ja) | 1995-06-13 | 1996-06-12 | 前赤血球段階のマラリアのポリペプチド分子 |
JP2008139896A Withdrawn JP2009000104A (ja) | 1995-06-13 | 2008-05-28 | 前赤血球段階のマラリアのポリペプチド分子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008139896A Withdrawn JP2009000104A (ja) | 1995-06-13 | 2008-05-28 | 前赤血球段階のマラリアのポリペプチド分子 |
Country Status (13)
Country | Link |
---|---|
US (3) | US6191270B1 (ja) |
EP (2) | EP1621547B1 (ja) |
JP (2) | JPH11508130A (ja) |
AT (2) | ATE302276T1 (ja) |
AU (1) | AU719163B2 (ja) |
CA (1) | CA2221029A1 (ja) |
DE (2) | DE69638127D1 (ja) |
DK (2) | DK0833917T3 (ja) |
ES (1) | ES2248816T3 (ja) |
FR (1) | FR2735478B1 (ja) |
HK (1) | HK1084403A1 (ja) |
PT (1) | PT833917E (ja) |
WO (1) | WO1996041877A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009000104A (ja) * | 1995-06-13 | 2009-01-08 | Inst Pasteur | 前赤血球段階のマラリアのポリペプチド分子 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2672290B1 (fr) * | 1991-02-05 | 1995-04-21 | Pasteur Institut | Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t. |
FR2697022B1 (fr) * | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
US20030161840A1 (en) * | 1992-10-19 | 2003-08-28 | Institut Pasteur | Plasmodium falciparum antigens inducing protective antibodies |
FR2771640B1 (fr) * | 1997-12-03 | 2000-02-11 | Inst Nat Sante Rech Med | Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques |
EP1201250A1 (en) * | 2000-10-25 | 2002-05-02 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Immunogenic compositions comprising liver stage malarial antigens |
WO2002092628A2 (fr) * | 2001-05-16 | 2002-11-21 | Institut Pasteur | Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques |
DK1350839T3 (da) | 2002-04-05 | 2010-07-12 | Pasteur Institut | Identificering af de virulensassocierede regioner RD1 og RD5, hvilket muliggør udvikling af forbedrede vacciner af M. bovis BCG og M. microti |
JP5116971B2 (ja) * | 2002-10-15 | 2013-01-09 | インターセル アーゲー | B群連鎖球菌の接着因子をコードする核酸、b群連鎖球菌の接着因子、およびその使用 |
KR101035111B1 (ko) * | 2004-06-30 | 2011-05-19 | 주식회사 엘지생명과학 | 말라리아 플라스모듐 팔시파룸의 면역학적 측정방법 및이에 사용되는 측정 수단 |
US8401159B2 (en) * | 2005-11-30 | 2013-03-19 | On-Q Telecom Systems Co., Inc. | Data provision to a virtual personal assistant for handling calls in a communication system |
EP2648744B1 (en) | 2010-12-06 | 2020-06-03 | MalVa GmbH | Malaria vaccines based on pre-erythrocytic antigens from p. falciparum |
CN117069819B (zh) * | 2023-09-13 | 2024-03-19 | 南华大学 | 一种黑腹狼蛛抗菌肽lc-amp-i1及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0014815A3 (de) * | 1978-12-20 | 1980-10-29 | Ciba-Geigy Ag | Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen |
US6270771B1 (en) * | 1988-10-06 | 2001-08-07 | Institut Pasteur | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes |
FR2672290B1 (fr) * | 1991-02-05 | 1995-04-21 | Pasteur Institut | Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t. |
FR2679909B1 (fr) * | 1991-07-31 | 1995-08-25 | Pasteur Institut | Polypeptides aptes a induire in vivo des anticorps inhibant l'invasion de globules rouges par des merozouites de p. falciparum, produits apparentes et leur application comme vaccin. |
FR2697022B1 (fr) * | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
FR2735478B1 (fr) * | 1995-06-13 | 1997-08-22 | Pasteur Institut | Molecules polypeptidiques de stade pre-erythrocytaire du paludisme |
-
1995
- 1995-06-13 FR FR9507007A patent/FR2735478B1/fr not_active Expired - Fee Related
-
1996
- 1996-06-12 DE DE69638127T patent/DE69638127D1/de not_active Expired - Lifetime
- 1996-06-12 EP EP05016651A patent/EP1621547B1/fr not_active Expired - Lifetime
- 1996-06-12 AU AU63096/96A patent/AU719163B2/en not_active Ceased
- 1996-06-12 ES ES96922107T patent/ES2248816T3/es not_active Expired - Lifetime
- 1996-06-12 CA CA002221029A patent/CA2221029A1/fr not_active Abandoned
- 1996-06-12 DK DK96922107T patent/DK0833917T3/da active
- 1996-06-12 US US08/973,462 patent/US6191270B1/en not_active Expired - Lifetime
- 1996-06-12 PT PT96922107T patent/PT833917E/pt unknown
- 1996-06-12 WO PCT/FR1996/000894 patent/WO1996041877A2/fr active IP Right Grant
- 1996-06-12 EP EP96922107A patent/EP0833917B1/fr not_active Expired - Lifetime
- 1996-06-12 AT AT96922107T patent/ATE302276T1/de not_active IP Right Cessation
- 1996-06-12 DK DK05016651.1T patent/DK1621547T3/da active
- 1996-06-12 DE DE69635077T patent/DE69635077T2/de not_active Expired - Lifetime
- 1996-06-12 JP JP9502711A patent/JPH11508130A/ja active Pending
- 1996-06-12 AT AT05016651T patent/ATE458002T1/de not_active IP Right Cessation
-
2000
- 2000-12-22 US US09/742,096 patent/US7056518B2/en not_active Expired - Fee Related
-
2005
- 2005-08-04 US US11/196,400 patent/US20050287166A1/en not_active Abandoned
-
2006
- 2006-06-12 HK HK06106687.9A patent/HK1084403A1/xx not_active IP Right Cessation
-
2008
- 2008-05-28 JP JP2008139896A patent/JP2009000104A/ja not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009000104A (ja) * | 1995-06-13 | 2009-01-08 | Inst Pasteur | 前赤血球段階のマラリアのポリペプチド分子 |
Also Published As
Publication number | Publication date |
---|---|
CA2221029A1 (fr) | 1996-12-27 |
US6191270B1 (en) | 2001-02-20 |
AU719163B2 (en) | 2000-05-04 |
DK1621547T3 (da) | 2010-06-07 |
AU6309696A (en) | 1997-01-09 |
DE69638127D1 (de) | 2010-04-01 |
FR2735478B1 (fr) | 1997-08-22 |
US20020155441A1 (en) | 2002-10-24 |
HK1084403A1 (en) | 2006-07-28 |
EP0833917B1 (fr) | 2005-08-17 |
ATE302276T1 (de) | 2005-09-15 |
US7056518B2 (en) | 2006-06-06 |
WO1996041877A3 (fr) | 1997-01-23 |
DK0833917T3 (da) | 2005-12-05 |
ATE458002T1 (de) | 2010-03-15 |
PT833917E (pt) | 2005-11-30 |
US20050287166A1 (en) | 2005-12-29 |
ES2248816T3 (es) | 2006-03-16 |
JP2009000104A (ja) | 2009-01-08 |
EP1621547B1 (fr) | 2010-02-17 |
DE69635077T2 (de) | 2006-05-18 |
DE69635077D1 (de) | 2005-09-22 |
EP1621547A1 (fr) | 2006-02-01 |
WO1996041877A2 (fr) | 1996-12-27 |
FR2735478A1 (fr) | 1996-12-20 |
EP0833917A2 (fr) | 1998-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009000104A (ja) | 前赤血球段階のマラリアのポリペプチド分子 | |
US7438917B2 (en) | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes | |
US6472519B1 (en) | Plasmodium falciparum antigens inducing protective antibodies | |
US5928901A (en) | Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by P. falciparum in hepatocytes and compositions containing them | |
JPH03173830A (ja) | ワクチン組成物 | |
Romero et al. | Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghei | |
CA1316631C (en) | Protein copolymer malaria vaccine | |
WO2000011179A1 (en) | RECOMBINANT MULTIVALENT MALARIAL VACCINE AGAINST $i(PLASMODIUM FALCIPARUM) | |
US7563440B2 (en) | Plasmodium falciparum antigens inducing protective antibodies | |
US5599543A (en) | Immunogenic four amino acid epitope against Plasmodium vivax | |
US5690941A (en) | Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by P. falciparum at the sporozoite stage and in the hepatocytes | |
JP2002371098A (ja) | マラリア感染診断材及びマラリア原虫の増殖を抑える免疫用抗原 | |
EP0353823A1 (en) | Immunologically active peptide conjugate PPD-(NANP)n useful as an antimalaria vaccine | |
Hajeer | Some Antigen: Antibody Reactions of Toxoplasma gondii | |
Chai | The humoral response to a chemically defined synthetic vaccine comprised of epitopes derived from the circumsporozoite protein of Plasmodium berghei | |
PT100757A (pt) | Polipeptidos aptos para induzir "in vivo"anticorpos capazes de inibir a invasao de globulos vermelhos por merozoitos de "p.falciparum", produtos aparentados e sua aplicacao na producao de composicoes de vacinacao |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070618 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070606 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070703 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080528 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080528 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080807 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20081113 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091021 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091029 |